Form 13-F position report

ROIVANT SCIENCES LTD

Reported by BAKER BROS ADVISORS LP

ROIV CUSIP G76279101 Manager CIK 0001263508

Reported 3,660,352 shares, down 1,056,479 (22.4%) from the prior quarter.

Reported value -19.8%; share count -22.4% vs. the prior quarter.

Reduced
% of reported 13F value 0.64% This manager · Q3 2026
Shares 3,660,352 Quarter-end amount reported
Reported value $133,859,073 Fair value at quarter end
Consecutive quarters held 16 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-12-31 5726057
2023-03-31 35257433
2023-06-30 95040207
2023-09-30 138725357
2023-12-31 85269660
2024-03-31 78141810
2024-06-30 29582428
2024-09-30 32297183
2024-12-31 44572755
2025-03-31 38016830
2025-06-30 42462802
2025-09-30 57006405
2025-12-31 120543869
2026-03-31 134835927
2026-06-30 166928649
2026-09-30 133859073

Quarterly position history

How this manager's reported quarter-end position changed over time.

16 quarters
Quarterly reported position history for ROIVANT SCIENCES LTD held by BAKER BROS ADVISORS LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 3,660,352 -1,056,479 (-22.4%) 0.64% $133,859,073 2026-11-16
Q2 2026 Reduced 4,716,831 -150,892 (-3.1%) 0.84% $166,928,649 2026-08-14
Q1 2026 Reduced 4,867,723 -687,294 (-12.4%) 0.77% $134,835,927 2026-05-15
Q4 2025 Added 5,555,017 +1,787,244 (47.4%) 0.71% $120,543,869 2026-02-17
Q3 2025 Unchanged 3,767,773 0 (0.0%) 0.41% $57,006,405 2025-11-14
Q2 2025 Unchanged 3,767,773 0 (0.0%) 0.41% $42,462,802 2025-08-14
Q1 2025 Unchanged 3,767,773 0 (0.0%) 0.42% $38,016,830 2025-05-15
Q4 2024 Added 3,767,773 +969,057 (34.6%) 0.48% $44,572,755 2025-02-14
Q3 2024 Unchanged 2,798,716 0 (0.0%) 0.33% $32,297,183 2024-11-14
Q2 2024 Reduced 2,798,716 -4,615,118 (-62.3%) 0.38% $29,582,428 2024-08-14
Q1 2024 Reduced 7,413,834 -179,190 (-2.4%) 0.98% $78,141,810 2024-05-15
Q4 2023 Reduced 7,593,024 -4,284,147 (-36.1%) 0.97% $85,269,660 2024-02-14
Q3 2023 Added 11,877,171 +2,448,579 (26.0%) 0.8% $138,725,357 2023-11-14
Q2 2023 Added 9,428,592 +4,651,162 (97.4%) 0.55% $95,040,207 2023-08-14
Q1 2023 Added 4,777,430 +4,060,777 (566.6%) 0.19% $35,257,433 2023-05-15
Q4 2022 New 716,653 +716,653 (0.0%) 0.03% $5,726,057 2023-02-14

Who else reported the position

597 managers reported ROIVANT SCIENCES LTD for Q3 2026.

Managers reporting ROIVANT SCIENCES LTD in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Added 85,575,553 +4,555,163 0.13% $3,129,497,953 20 qtrs
BlackRock Inc Added 61,879,232 +13,643,141 0.03% $2,262,923,497 9 qtrs
MORGAN STANLEY Reduced 38,603,606 -3,989,299 0.07% $1,411,733,957 20 qtrs
QVT Financial LP Unchanged 23,723,074 0 48.22% $867,552,816 20 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 23,127,563 +1,004,365 0.02% $845,774,979 3 qtrs
STATE STREET CORPORATION Added 22,399,587 +4,603,612 0.02% $819,152,897 20 qtrs
FARALLON CAPITAL MANAGEMENT LLC Added 21,745,533 +7,436,533 3.43% $795,234,142 14 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 21,657,255 +15,916 0.04% $792,005,815 3 qtrs
UBS Group AG Reduced 13,928,426 -3,538,215 0.07% $509,362,539 16 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 12,521,620 +847,240 0.02% $467,988,217 20 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
SHS

Voting authority reported

Sole
3,660,352
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.